文献速递前列腺癌

前列腺癌淋巴结复发挽救性淋巴结清扫最佳候选者的识别:大型多中心分析

Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.
PubMed 文献 · Eur Urol · 2018-10-06

该研究纳入654例根治性前列腺切除术后PSA升高且PET/CT证实淋巴结复发并接受挽救性淋巴结清扫(SLND)的患者。术后1年内早期临床复发(eCR)的Kaplan-Meier概率为25%,eCR与3年癌症特异性死亡风险升高相关(20% vs 1.4%,p<0.0001)。研究基于术前常规特征开发了首个预测eCR的风险计算器(C指数0.75),用于筛选最适合SLND的患者。

要点

  • SLND术后约25%的患者在1年内出现早期临床复发。
  • eCR患者3年癌症特异性死亡率显著高于无eCR者(20% vs 1.4%)。
  • 基于6项术前特征的风险计算器可辅助筛选SLND获益人群。

核心结论

  • 约25%的患者在SLND术后1年内发生早期临床复发。
  • 研究开发了首个基于术前常规特征的风险分层工具以识别SLND最佳候选者。
  • 该工具有助于避免对即使经影像引导仍更可能进展的患者实施SLND。

研究设计与样本

  • 多中心回顾性分析,纳入9家三级转诊中心的654例患者。
  • 患者均为根治性前列腺切除术后出现PSA升高且经11C-胆碱或68Ga-PSMA配体PET/CT记录淋巴结复发者。
  • 研究终点为SLND术后1年内发生的早期临床复发(eCR)。
  • 采用多因素Cox回归建立预测模型并开发风险计算器,用决策曲线分析评估净获益。

主要发现

  • 无临床复发患者的中位随访为30个月(四分位距16-50)。
  • 334例患者发生临床复发,其中150例为SLND术后1年内的eCR。
  • eCR的Kaplan-Meier概率为25%。
  • eCR与3年癌症特异性死亡风险升高相关(20% vs 1.4%,p<0.0001)。
  • 多因素分析中Gleason分级分组5(HR 2.04;p<0.0001)、从RP到PSA升高的时间(HR 0.99;p=0.025)、PSA升高时接受激素治疗(HR 1.47;p=0.0005)、PET/CT示腹膜后摄取(HR 1.24;p=0.038)、PET/CT示3个及以上阳性病灶(HR 1.26;p=0.019)及SLND时PSA水平(HR 1.05;p<0.0001)为SLND后CR的显著预测因子。

关键数值与推荐

  • 模型区分度Harrel's C指数为0.75。
  • 决策曲线分析显示该模型在所有阈值概率下净获益均高于「全部治疗」策略。
  • 风险计算器用于预测SLND术后1年eCR。

临床怎么用

  • 可利用该风险计算器基于术前常规特征评估SLND术后1年eCR风险。
  • 对预测早期进展风险高的患者可考虑避免SLND。
  • 该工具可辅助识别最可能从SLND获益的患者。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Salvage lymph node dissection (SLND) represents a possible treatment option for prostate cancer patients affected by nodal recurrence after local treatment. However, SLND may be associated with intra- and postoperative complications, and the oncological benefit may be limited to specific groups of patients. OBJECTIVE: To identify the optimal candidates for SLND based on preoperative characteristics. DESIGN, SETTING, AND PARTICIPANTS: The study included 654 patients who experienced prostate-specific antigen (PSA) rise and nodal recurrence after radical prostatectomy (RP) and underwent SLND at nine tertiary referral centers. Lymph node recurrence was documented by positron emission tomography/computed tomography (PET/CT) scan using either 11C-choline or 68Ga-labeled prostate-specific membrane antigen ligand. INTERVENTION: SLND. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The study outcome was early clinical recurrence (eCR) developed within 1 yr after SLND. Multivariable Cox regression analysis was used to develop a predictive model. Multivariable-derived coefficients were used to develop a novel risk calculator. Decision-curve analysis was used to evaluate the net benefit of the predictive model. RESULTS AND LIMITATIONS: Median follow-up was 30 (interquartile range, 16-50) mo among patients without clinical recurrence (CR), and 334 patients developed CR after SLND. In particular, eCR at 1 yr after SLND was observed in 150 patients, with a Kaplan-Meier probability of eCR equal to 25%. The development of eCR was significantly associated with an increased risk of cancer-specific mortality at 3 yr, being 20% versus 1.4% in patients with and without eCR, respectively (p<0.0001). At multivariable analysis, Gleason grade group 5 (hazard ratio [HR]: 2.04; p<0.0001), time from RP to PSA rising (HR: 0.99; p=0.025), hormonal therapy administration at PSA rising after RP (HR: 1.47; p=0.0005), retroperitoneal uptake at PET/CT scan (HR: 1.24; p=0.038), three or more positive spots at PET/CT scan (HR: 1.26; p=0.019), and PSA level at SLND (HR: 1.05; p<0.0001) were significant predictors of CR after SLND. The coefficients of the predictive model were used to develop a risk calculator for eCR at 1 yr after SLND. The discrimination of the model (Harrel'sC index) was 0.75. At decision-curve analysis, the net benefit of the model was higher than the "treat-all" option at all the threshold probabilities. CONCLUSIONS: We reported the largest available series of patients treated with SLND. Roughly 25% of men developed eCR after surgery. We developed the first risk stratification tool to identify the optimal candidate to SLND based on routinely available preoperative characteristics. This tool can be useful to avoid use of SLND in men more likely to progress despite any imaging-guided approach. PATIENT SUMMARY: The risk of early recurrence after salvage lymph node dissection (SLND) was approximately 25%. In this study, we developed a novel tool to predict the risk of early failure after SLND. This tool will be useful to identify patients who would benefit the most from SLND from other patients who should be spared from surgery.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Fossati N, Suardi N, Gandaglia G, et al. Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. Eur Urol. 2018. PMID: 30301694. doi:10.1016/j.eururo.2018.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。